Latest hereditary angioedema Stories
A new drug, increasing use, extreme costs highlight need for integrated claims data to better identify people with the disorder, develop clinical programs that improve care, reduce costs
CARLSBAD, Calif., May 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKK(Rx).
Third annual awareness day shines a light on rare, potentially life-threatening condition KING OF PRUSSIA, Pa., May 14, 2014 /PRNewswire/ -- As a Diamond Sponsor of HAE Day on May 16, 2014,
Analysis also reveals decrease in emergency room visits and hospitalizations SAN DIEGO, March 1, 2014 /PRNewswire/ -- Findings announced by CSL Behring today show that current hereditary
International study by CSL Behring is world's first placebo-controlled phase III trial to examine subcutaneous administration of C1-INH for use in treating rare, sometimes life-threatening, condition
- An armed gangster.